A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Condition(s):Advanced Solid TumorsLast Updated:March 15, 2024Active, not recruiting